Guided Therapeutics (GTHP) Receivables - Net (2016 - 2025)

Guided Therapeutics' Receivables - Net history spans 16 years, with the latest figure at $4000.0 for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 33.33% to $4000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4000.0, a 33.33% increase, with the full-year FY2025 number at $4000.0, up 33.33% from a year prior.
  • Receivables - Net hit $4000.0 in Q4 2025 for Guided Therapeutics, down from $6000.0 in the prior quarter.
  • Over the last five years, Receivables - Net for GTHP hit a ceiling of $165.0 million in Q1 2022 and a floor of $2000.0 in Q3 2024.
  • Historically, Receivables - Net has averaged $15.7 million across 5 years, with a median of $7221.0 in 2023.
  • Biggest five-year swings in Receivables - Net: skyrocketed 130852.38% in 2022 and later plummeted 99.97% in 2023.
  • Tracing GTHP's Receivables - Net over 5 years: stood at $171153.0 in 2021, then plummeted by 96.31% to $6312.0 in 2022, then grew by 17.9% to $7442.0 in 2023, then crashed by 59.69% to $3000.0 in 2024, then soared by 33.33% to $4000.0 in 2025.
  • Business Quant data shows Receivables - Net for GTHP at $4000.0 in Q4 2025, $6000.0 in Q3 2025, and $8000.0 in Q2 2025.